Congress is looking to give the Food and Drug Administration the controversial and complex job of controlling tobacco marketing and advertising. FDA would not be able to ban cigarettes or require zero nicotine products, under legislation recently approved by a key House committee. But it would gain authority to approve cigarette labeling, limit certain promotional claims and curb marketing to minors. The measure provides legal authority for a regulatory approach devised more than 10 years ago under former FDA Commissioner David Kessler, but subsequently struck down by the courts.
Congress is looking to give the Food and Drug Administration the controversial and complex job of controlling tobacco marketing and advertising. FDA would not be able to ban cigarettes or require zero nicotine products, under legislation recently approved by a key House committee. But it would gain authority to approve cigarette labeling, limit certain promotional claims and curb marketing to minors. The measure provides legal authority for a regulatory approach devised more than 10 years ago under former FDA Commissioner David Kessler, but subsequently struck down by the courts.
Since then, a coalition of health groups, antismoking organizations and Democratic legislators have pushed for legislation to firmly establish federal control over tobacco marketing. To offset concerns raised by the Bush administration and FDA Commissioner Andrew von Eschenbach that the agency lacks the resources to take on such a heavy new burden, the bill authorizes new user fees to support the program. Tobacco companies would contribute some $85 million in the first year and increasing fees thereafter. Marlboro producer Philip Morris, part of the Altria Group, supports FDA regulation, while Reynolds American and others oppose it. Some Republicans may try to block the legislation if it moves forward. The White House has stated opposition to the measure, but President Bush might not want to veto a bill to curb smoking as he leaves Washington.
Lenacapavir HIV PrEP: Not an AIDS Vaccine, but Vaccine Adjacent
June 19th 2025Experts and advocates say that twice-a-year HIV PrEP injections have the prevention potential of a vaccine — and that a once-a-year version of lenacapavir would be even better. But will Yeztugo be available to the people who would benefit most from HIV PrEP?
Read More
Conversations With Perry and Friends: Paul Fronstin, Ph.D.
May 9th 2025Perry Cohen, Pharm.D., a longtime member of the Managed Healthcare Executive editorial advisory board, is host of the Conversations with Perry and Friends podcast. In this episode, his guest is Paul Fronstin, Ph.D., director of health benefits research at the Employee Benefit Research Institute.
Listen
Conversations With Perry and Friends
April 14th 2025Perry Cohen, Pharm.D., a longtime member of the Managed Healthcare Executive editorial advisory board, is host of the Conversations with Perry and Friends podcast. His guest this episode is John Baackes, the former CEO of L.A. Care Health Plan.
Listen